Innoviva (INVA) Long-Term Deferred Tax (2011 - 2025)
Innoviva posted quarterly Long-Term Deferred Tax of $8.0 million for Q3 2025, down 46.34% year-on-year from $14.9 million in Q3 2024, and down 38.27% on a QoQ basis from $12.9 million in Q2 2025.
Innoviva (INVA) has 10 years of Long-Term Deferred Tax data on file, last reported at $8.0 million in Q3 2025.
- For the quarter ending Q3 2025, Long-Term Deferred Tax fell 46.34% year-over-year to $8.0 million; the trailing twelve-month figure through Sep 2025 stood at $8.0 million (down 46.34% YoY), and the FY2025 full-year result was $8.0 million, down 46.34% from the prior year.
- Long-Term Deferred Tax for Q3 2025 stood at $8.0 million, down from $12.9 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $74.0 million in Q1 2021 and bottomed at $5.0 million in Q3 2023.
- The 5-year median for Long-Term Deferred Tax is $13.9 million (2024), against an average of $21.2 million.
- The widest annual swing landed in 2021, when Long-Term Deferred Tax plunged 81.52%; it then jumped 200.38% in 2024.
- A 5-year view of Long-Term Deferred Tax shows it stood at $17.3 million in 2021, then surged by 34.32% to $23.3 million in 2022, then plunged by 78.72% to $5.0 million in 2023, then soared by 143.42% to $12.1 million in 2024, then plunged by 33.78% to $8.0 million in 2025.
- The last three Long-Term Deferred Tax figures came in at $8.0 million (Q3 2025), $12.9 million (Q2 2025), and $12.3 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.98 Mn |
| Jun 30, 2025 | 12.93 Mn |
| Mar 31, 2025 | 12.29 Mn |
| Dec 31, 2024 | 12.05 Mn |
| Sep 30, 2024 | 14.88 Mn |
| Jun 30, 2024 | 11.45 Mn |
| Sep 30, 2023 | 4.95 Mn |
| Jun 30, 2023 | 6.33 Mn |
| Jun 30, 2022 | 23.27 Mn |
| Mar 31, 2022 | 22.40 Mn |
| Dec 31, 2021 | 17.33 Mn |
| Sep 30, 2021 | 28.16 Mn |
| Jun 30, 2021 | 48.69 Mn |
| Mar 31, 2021 | 74.02 Mn |
| Dec 31, 2020 | 93.76 Mn |
| Sep 30, 2020 | 109.49 Mn |
| Jun 30, 2020 | 118.35 Mn |
| Mar 31, 2020 | 138.24 Mn |
| Dec 31, 2019 | 154.17 Mn |
| Sep 30, 2019 | 166.56 Mn |
| Jun 30, 2019 | 177.11 Mn |
| Mar 31, 2019 | 187.55 Mn |
| Dec 31, 2018 | 196.05 Mn |
| Dec 31, 2012 | 4.00 Mn |
| Dec 31, 2011 | 56.00 Mn |